CVS Health announced it will split into two publicly traded companies by 2028, separating its pharmacy business from its insurance and healthcare services. The breakup caused a $15 billion market value drop on announcement day, reflecting investor concerns over costs and uncertain benefits. The split is designed to be tax-free and aims to create two focused companies with solid credit ratings and attractive dividends. Investors should watch for details on share ratios, debt allocation, and dividend policies before making decisions.
CVS shares are trading at USD 85.70 with a slight gain of 0.53% as of Nov 10, 2026 19:11 WIB on Pluang, showing some resilience after the breakup announcement. The stock's dividend yield stands at 3.12%, and investors on Pluang are predominantly buying, with 68% of order activity in favor. This trading behavior provides a current snapshot of market sentiment following the company's plan to split into two focused entities.
